EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

A multi-centred retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis

Aditi Kumar iD, Joshua Baxter, Peter Rimmer, Ben Noble, Joshua Bower, Mujeeb Ullah Makki, Ayiesha Hatta, Anmol Chikhlia, Jonathan Cheesbrough, Ben Disney, Josh Muir, Mariya Karova und 13 weitere

Crohn's & Colitis 360 · 26.05.2026

DOI: 10.1093/crocol/otag045 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Crohn's & Colitis 360, online erschienen am 26.05.2026. Verfasst von Aditi Kumar und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tofacitinib, filgotinib and upadacitinib are JAK inhibitors (JAKi) that have demonstrated efficacy in ulcerative colitis (UC) against placebo. This study aims to compare the clinical efficacy between these drugs.

Methods

This is a multi-centred, retrospective cohort study. Patients with UC starting a JAKi were recruited between 2018 and 2024 when starting their first JAKi. Clinical remission and response, based on clinical scores, calprotectin and endoscopic measurement were assessed at 3- and 6-months. Both independent and combined variable outcomes were analysed.

Results

270 patients were included in the analysis, of which 70 (26%) were on upadacitinib, 51 (19%) on filgotinib and 149 (55%) on tofacitinib. Clinical, biochemical and endoscopic remission at 6-months was 91%, 71% and 80% for upadacitinib; 78%, 67% and 50% for filgotinib; 73%, 51% and 44% for tofacitinib. Upadacitinib demonstrated significantly greater clinical response (p = 0.027) and remission (p = 0.037) rates at 6-months than tofacitinib. Drug persistence at 12-months was 86% for upadacitinib, 72% for filgotinib and 69% for tofacitinib. Upadacitinib demonstrated significantly greater 6-month remission rates compared to tofacitinib in the bio-exposed cohort (71% v 52%, p = 0.022) and in the bio-naïve cohort (93% v 50%, p = 0.009). The incidence rates for hospital admissions were 10.2, 21.9, and 14.1 and for colectomies were 6.7, 10.0 and 5.0 per 1000 patient months at risk for upadacitinib, filgotinib and tofacitinib, respectively.

Conclusion

This study demonstrates that upadacitinib is more likely to achieve 6-month response and remission compared to tofacitinib. In both bio-naïve and bio-exposed patients, upadacitinib was more likely to achieve remission at 6-months. The efficacy of JAKi does not appear diminished by prior biologic use.

Schlagwörter

Stichwörter der Autor:innen

JAK inhibitorsfilgotinibinflammatory bowel diseasetofacitinibulcerative colitisupadacitinib

Autor:innen und Institutionen

  • Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK.
  • Department of Gastroenterology, Walsall Manor NHS Trust, Walsall, UK.
  • Department of Gastroenterology, Queen Elizabeth Hospital Birmingham, Birmingham, UK.
  • Department of Gastroenterology, University Hospitals Coventry & Warwickshire, Coventry, UK.
  • Department of Gastroenterology, Shrewsbury & Telford NHS Trust, Shrewsbury, UK.
  • Department of Gastroenterology, Sandwell General Hospital, Birmingham, UK.

ORCID-Profile: Aditi Kumar, Philip Harvey

Zitieren

APA

Kumar, A., Baxter, J., Rimmer, P., Noble, B., Bower, J., Makki, M. U., Hatta, A., Chikhlia, A., Cheesbrough, J., Disney, B., Muir, J., Karova, M., Butterworth, J., Sagar, N., Al-Talib, I., Nahal, J., Ali, N., Sagar, V., Varyani, F., …, & Harvey, P. (2026). A multi-centred retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis. Crohn's & Colitis 360. https://doi.org/10.1093/crocol/otag045

Vancouver

Kumar A, Baxter J, Rimmer P, Noble B, Bower J, Makki MU, et al. A multi-centred retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis. Crohn's & Colitis 360. 2026. doi:10.1093/crocol/otag045

BibTeX
@article{Kumar2026,
  author = {Kumar, Aditi and Baxter, Joshua and Rimmer, Peter and Noble, Ben and Bower, Joshua and Makki, Mujeeb Ullah and Hatta, Ayiesha and Chikhlia, Anmol and Cheesbrough, Jonathan and Disney, Ben and Muir, Josh and Karova, Mariya and Butterworth, Jeffrey and Sagar, Nidhi and Al-Talib, Ismaeel and Nahal, Jasbir and Ali, Nasima and Sagar, Vandana and Varyani, Fumi and Smith, Sam and Bourne, Stephanie and Hsu, Yu-Kai and Eltahir, Almoiez and de Silva, Shanika and Harvey, Philip},
  title = {A multi-centred retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitis},
  journal = {Crohn's & Colitis 360},
  year = {2026},
  doi = {10.1093/crocol/otag045}
}
Kostenlos starten →